Selected Publications

Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling YL, Cappelleri JC, Sanchez-Riera L, Masri KR, Hughes M, Massey N.: Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe. Rheumatology (Oxford) 65: keag106, Mar 2026.

Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease PJ.: Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data. Adv Ther Mar 2026.

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB.: Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study. Arthritis Rheumatol Feb 2026.

Mease P, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A.: Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther 2026.

Leung YY, Haugegaard T, Annfeldt TK, Holland R, Strand V, Mease P, Tugwell P, Wells GA, Shea BJ, Mathew AJ, Goel N, Lindsay C, Ogdie A, Orbai AM, Coates LC, Gladman DD, Tillett W, Chau J, Christensen R.: Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study. Semin Arthritis Rheum 2026.

Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC.: Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials. Rheumatol Ther Dec 2025.

Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO.: Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study. J Rheumatol 53: 232, Dec 2025.

Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ.: Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther Dec 2025.

Gossec L, Balanescu A, D'Agostino MA, Ogdie A, Sewerin P, Deng Y, Shi L, Sugimoto Y, Zhong S, Xing Y, Lippe R, Kishimoto M.: Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials. Arthritis Res Ther Nov 2025.

McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF.: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nat Med Oct 2025.